Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03261999 · ClinicalTrials.gov registry record · Phase 3
Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer
A Phase 3 study, sponsored by Foresee Pharmaceuticals Co..
- Completed
- Registry status
- Phase 3
- Development phase
- 144
- Enrollment target
NCT03261999 is a Phase 3 study that has completed, run by Foresee Pharmaceuticals Co.. The registered enrollment target is 144 participants.
The verdict
NCT03261999, a Phase 3 study, has completed, sponsored by Foresee Pharmaceuticals Co..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 144 participants
- Enrollment target
Study Summary
The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with prostate cancer, when administered as two injections twelve weeks apart.
Interventions
- DRUG Leuprolide Mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2017-09-26 |
| Est. Completion | 2019-02-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03261999
The ClinicalTrials.gov registry entry for NCT03261999 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Foresee Pharmaceuticals Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Leuprolide Mesylate is the first listed.
NCT03261999 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03261999 about?
NCT03261999 is a clinical study titled "Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer". The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with prostate cancer, when administered as two injections twelve weeks apart.
What is the current status of trial NCT03261999?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 144 participants. The study started on 2017-09-26. Estimated completion is 2019-02-01.
What interventions are being tested in trial NCT03261999?
The interventions under investigation include: Leuprolide Mesylate (DRUG).
Who is sponsoring clinical trial NCT03261999?
This trial is sponsored by Foresee Pharmaceuticals Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.